Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Results From the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

ROCKET AF Investigators, Matthew W Sherwood, James D Douketis, Manesh R Patel, Jonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, Alex C Spyropoulos, Graeme J Hankey, Daniel E Singer, Christopher C Nessel, Kenneth W Mahaffey, Keith A A Fox, Robert M Califf, Richard C Becker

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Results From the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)'. Together they form a unique fingerprint.

Medicine & Life Sciences